Treatment Satisfaction Among Patients Using Anti-Inflammatory Topical Medications for Dry Eye Disease
Open Access
- 1 March 2020
- journal article
- research article
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 14, 875-883
Abstract
Purpose: To assess patient satisfaction among current and former users of the anti-inflammatory topical medications, cyclosporine A 0.05% (CYC) and lifitegrast 5.0% (LIF), for the management of dry eye disease (DED). Patients and Methods: Patients with DED were recruited via physician referral to participate in a survey. Current users of CYC or LIF were asked to rate their experience in terms of satisfaction, side effects, and limitation of activities. Switchers of CYC to LIF or LIF to CYC were asked to rate the importance of potential reasons for switching. Results: Surveys were completed by 207 patients currently treated with CYC (n=98), LIF (n=96), or other DED medications (n=13). Although overall satisfaction with current treatment was high, current users of CYC and LIF reported ineffective relief of DED symptoms (31% and 22%, respectively) and dissatisfaction with the time to onset of effect (29% and 11%). Substantial proportions of patients reported ‘sometimes’, “usually”, or ‘always’ experiencing the following side effects: burning sensation (72% CYC, 64% LIF), itching (43% CYC, 44% LIF), altered sensation of taste (21% CYC, 56% LIF), blurred vision (37% CYC, 50% LIF), and discharge (28% CYC, 30% LIF). Of the 30 switchers of CYC to LIF and 31 switchers of LIF to CYC, the majority reported inability to relieve DED symptoms as a very or extremely important switching reason. Despite switching, one in four patients were somewhat dissatisfied or dissatisfied with their current medication, with 37% of patients reporting ineffective symptom relief. Conclusion: Although the rate of overall satisfaction was generally high with both LIF and CYC, many patients were unable to achieve effective symptom relief and commonly experienced side effects. The proportion of patients who were dissatisfied and/or unable to achieve effective symptom relief even after switching suggests the need for additional treatment options for managing DED.Keywords
This publication has 34 references indexed in Scilit:
- Dry Eye Disease and Work Productivity Loss in Visual Display Users: The Osaka StudyAmerican Journal of Ophthalmology, 2014
- Assessment of Vision-Related Quality of Life in Dry Eye PatientsInvestigative Ophthalmology & Visual Science, 2012
- Visual Problems in Young Adults due to Computer UseKlinische Monatsblätter für Augenheilkunde, 2012
- Work productivity loss in patients with dry eye disease: an online surveyCurrent Medical Research and Opinion, 2011
- Cyclosporine 0.05% Ophthalmic Emulsion for Dry Eye in Korea: A Prospective, Multicenter, Open-Label, Surveillance StudyKorean Journal of Ophthalmology, 2011
- Impact of Dry Eye Syndrome on Vision-Related Quality of LifeAmerican Journal of Ophthalmology, 2007
- Self-reported compliance with topical cyclosporine emulsion 0.05% and onset of the effects of increased tear production as assessed through patient surveysClinical Therapeutics, 2006
- Dysfunctional Tear SyndromeCornea, 2006
- Phase III Safety Evaluation of Cyclosporine 0.1% Ophthalmic Emulsion Administered Twice Daily to Dry Eye Disease Patients for Up to 3 YearsOphthalmology, 2005
- Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease11Reprint requests to: Linda Lewis, 575 Anton Blvd, Suite 900, Costa Mesa, CA 92626.Ophthalmology, 2000